LENZ Therapeutics (LENZ) Free Cash Flow (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Free Cash Flow of -$33.6 million for Q1 2026, down 107.82% year-over-year from $429.6 million in Q1 2025, and down 4.17% quarter-over-quarter from -$32.2 million in Q4 2025.
LENZ Therapeutics (LENZ) Free Cash Flow (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Free Cash Flow for 7 consecutive years, with -$33.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 107.82% year-over-year to -$33.6 million; the TTM figure through Mar 2026 stood at -$86.6 million (down 66.26% YoY), while the FY2025 annual figure was -$69.2 million, down 15.55% from the prior year.
- Free Cash Flow retreated to -$33.6 million in Q1 2026 per LENZ's latest filing, from -$32.2 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$9.2 million in Q3 2025 and bottomed at -$33.6 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$18.7 million across 5 years, with a median of -$16.2 million in 2025.
- Annual changes were most pronounced in 2024 — Free Cash Flow surged 56.0% — and 2025, when it sank 249.37%.
- LENZ Therapeutics' Free Cash Flow stood at -$23.4 million in 2022, then rose by 10.58% to -$21.0 million in 2023, then soared by 56.0% to -$9.2 million in 2024, then tumbled by 249.37% to -$32.2 million in 2025, then fell by 4.17% to -$33.6 million in 2026.
- Business Quant data shows LENZ's Free Cash Flow at -$33.6 million in Q1 2026, -$32.2 million in Q4 2025, and -$9.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn | -38.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -38.73 Mn |
| Jun 30, 2026 | -38.73 Mn |
| Mar 31, 2026 | -33.58 Mn |
| Mar 31, 2026 | -33.58 Mn |
| Dec 31, 2025 | -32.24 Mn |
| Dec 31, 2025 | -32.24 Mn |
| Sep 30, 2025 | -9.17 Mn |
| Sep 30, 2025 | -9.17 Mn |
| Jun 30, 2025 | -11.60 Mn |
| Jun 30, 2025 | -11.60 Mn |
| Mar 31, 2025 | -16.16 Mn |
| Mar 31, 2025 | -16.16 Mn |
| Dec 31, 2024 | -9.23 Mn |
| Dec 31, 2024 | -9.23 Mn |
| Sep 30, 2024 | -10.90 Mn |
| Sep 30, 2024 | -10.90 Mn |
| Jun 30, 2024 | -15.80 Mn |
| Jun 30, 2024 | -15.80 Mn |
| Mar 31, 2024 | -23.94 Mn |
| Mar 31, 2024 | -23.94 Mn |